The Royal Pharmaceutical Society (RPS) has written to Lord Bethell, Parliamentary Under Secretary of State for Innovation, to express ethical concerns about the proposed takeover of Vectura.
This intervention from the RPS has come after moves recently by tobacco company Philip Morris International to acquire Vectura, a UK company that makes products used in the treatment of asthma, COPD and other respiratory diseases.
RPS have said that tobacco companies should not profit from the illnesses their products cause, and if this takeover were allowed to proceed, it would send all the wrong signals for the kind of health and research community the UK seeks to promote.
RPS President Claire Anderson said:
“We are deeply concerned about the proposed takeover of Vectura by Philip Morris International.
“This takeover not only raises ethical concerns that a company whose tobacco products harm the public may later profit from providing treatment but also creates an ethical dilemma for healthcare professionals.
“We strongly urge the Government to oppose this takeover to protect the public and healthcare professionals.”